Trius Therapeutics plans IPO to raise up to $86.3 million for Phase III antibiotic
This article was originally published in Scrip
Executive Summary
Trius Therapeutics, a developer of antibiotics, has filed with US regulators for an IPO to raise up to $86.3 million. The San Diego company plans to use the proceeds to fund its treatment for serious Gram-positive infections, torezolid phosphate.